Independent Conference Highlights of the 2022 ASH Annual Meeting *

December 10-13, 2022; New Orleans, Louisiana
Review slidesets and expert analyses of key studies from the 2022 Hematology Annual Meeting.

Share

Program Content

Activities

ASH 2022: Key Studies
An Expert’s Guide to ASH 2022: Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 07, 2022

Expires: December 06, 2023

11 Capsule Summary Slidesets

Activities

PhaseED-Seq MRD in DLBCL
Pooled Analysis of PhaseED-Seq MRD-Negativity Assessment as Surrogate Endpoint After Frontline Induction Therapy in Patients With DLBCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

CAPTIVATE MRD Cohort
CAPTIVATE: 5-Yr Follow-up of Continued Ibrutinib vs Placebo in Patients With CLL/SLL and Undetectable MRD After First-line Ibrutinib + Venetoclax
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2022

Expires: December 13, 2023

BV + AVD in Unfavorable-Risk cHL
Extended Follow-up Results From a Pilot Study of Brentuximab Vedotin + AVD in Newly Diagnosed, Early-Stage, Unfavorable-Risk cHL Using Baseline MTV and PET2 Evaluation
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

TRIANGLE
TRIANGLE: Phase III Trial of Ibrutinib + CIT With or Without ASCT vs CIT Followed by ASCT in Younger Patients With Previously Untreated MCL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

AVO in High-Risk CLL
Phase II Trial: Updated Results of Frontline Acalabrutinib, Venetoclax, and Obinutuzumab in Patients With Untreated High-Risk CLL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

Acalabrutinib/LenR in MCL
Acalabrutinib + Lenalidomide and Rituximab With MRD Monitoring in Previously Untreated Mantle Cell Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

Phase I/II EPCORE NHL-2
Phase I/II EPCORE NHL-2 Trial Update: Epcoritamab + Rituximab/Lenalidomide in Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

AN + AD for cHL
Phase II Study of Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine as Frontline Combination Therapy for Advanced-Stage cHL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

SYMPHONY-1: Phase Ib Results
SYMPHONY-1: Phase Ib Results of Tazemetostat + Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

MATRix/IELSG43
MATRix/IELSG43: Phase III Trial of High-Dose Chemotherapy + ASCT vs Nonmyeloablative Chemoimmunotherapy as Consolidation for Primary CNS Lymphoma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

ALPINE: Final Analysis
ALPINE: Final Analysis of Zanubrutinib vs Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

Activities

ASH 2022: Lymphomas and CLL
Key Studies in Lymphomas and CLL: Independent Conference Coverage of ASH 2022
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 17, 2023

Expires: April 16, 2024

10 Capsule Summary Slidesets

Activities

DSMM XIII: Rd + ASCT + R vs Cont Rd
DSMM XIII: Phase III Trial of Rd Induction + ASCT With MEL140 Followed by R Maintenance vs Continuous Rd in Patients 60-75 Yr of Age With Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2022

Expires: December 11, 2023

Phase II GEM-CESAR
Phase II GEM-CESAR: Post Hoc Analyses of Sustained uMRD at 4 Yr After KRd + ASCT for High-Risk MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

ASCENT: Dara-KRd in SMM
ASCENT: Phase II Study of Fixed-Duration Therapy With Daratumumab/Carfilzomib/Lenalidomide/Dexamethasone for High-Risk Smoldering MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

KarMMa-2 Cohort 2a
Phase II KarMMa-2 Cohort 2a: Idecabtagene Vicleucel in Patients With Multiple Myeloma With Early Relapse After Frontline ASCT
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

UK OPTIMUM/MUKnine: Dara-VRd in Ultra-High‒Risk NDMM
UK OPTIMUM/MUKnine: Phase II Trial of Intensified Dara-VRd Consolidation After ASCT in Ultra-High‒Risk Newly Diagnosed Multiple Myeloma and Primary Plasma Cell Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

MonumenTAL-1: Talquetamab
MonumenTAL-1: Phase I/II Study of GPCR5D x CD3 Bispecific Antibody Talquetamab in Patients With Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

IFM 2017-03: Dara + Len Without Dex
IFM 2017-03: Phase III Trial of Daratumumab + Lenalidomide vs Lenalidomide + Dexamethasone in Frail Patients With Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

Ide-Cel After BCMA-TT
Real-world Multicenter Retrospective Study of Idecabtagene Vicleucel in Patients With R/R MM After Previous BCMA-Targeted Therapy Exposure
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

Mezigdomide + Dex in RR MM
Phase I/II Trial of Mezigdomide + Dexamethasone in R/R MM: Preliminary Results From the Dose-Expansion Phase II Cohort
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

Myeloma XI: Len Maintenance
Myeloma XI: Exploring Optimal Duration of Lenalidomide Maintenance After ASCT From Phase III Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

Activities

ASH 2022: Multiple Myeloma
Key Studies in Multiple Myeloma: Independent Conference Coverage of ASH 2022
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 21, 2023

Expires: March 20, 2024

11 Capsule Summary Slidesets

Activities

Ziftomenib in AML
Phase I/II KOMET-001: First-in-Human Study of Ziftomenib, a Novel KMT2A-Menin Inhibitor, in Relapsed/Refractory AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2022

Expires: December 11, 2023

ASC4MORE: Addition of Asciminib to Imatinib
ASC4MORE: Phase II Trial of Addition of Asciminib to Imatinib vs Continued Imatinib vs Switch to Nilotinib in Patients With Chronic-Phase CML Not Achieving Deep Molecular Responses With ≥1 Yr of Imatinib Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

AUGMENT-101: Revumenib
AUGMENT-101: Phase I Study of Revumenib in Patients With KMT2A-Rearranged or NPM1-Mutant AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

Gilteritinib/Aza/Ven/ in <em>FLT3</em>-Mut AML
Phase I/II Trial of Triplet Combination of Gilteritinib + Azacitidine/Venetoclax in Patients With FLT3-Mutated AML: Updated Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

ECOG-ACRIN E1910
ECOG-ACRIN E1910: Phase III Study of Consolidation Chemotherapy ± Blinatumomab in MRD-Negative BCR::ABL1-Negative B-ALL
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

GRAALL-2014/B QUEST
GRAALL-2014/B Quest Cohort Analysis: Blinatumomab During Consolidation in Adults With High-Risk Ph-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

V-FAST FLT3 Subgroup
V-FAST Subgroup Analysis: CPX-351 + Midostaurin in Newly Diagnosed AML by FLT3 Mutation
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

Low-Dose Dasatinib in CML
Low-Dose Dasatinib for Newly Diagnosed CML: Long-term Follow-up Outcomes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

VIALE-A Extended Follow-up
VIALE-A: Extended Follow-up of Azacitidine ± Venetoclax in Patients With Treatment-Naive AML Ineligible for Standard Induction Chemotherapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

PhI/II AZA/VEN/MAG
Phase I/II Trial of Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed/Refractory AML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

GMALL-INITIAL1
GMALL-INITIAL1: Inotuzumab Ozogamicin Induction Therapy Followed by Standard Chemotherapy in Older Patients With B-Lymphoblastic Leukemia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

Activities

ASH 2022 Leukemia Highlights
Key Studies in Leukemias: Independent Conference Coverage of ASH 2022
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 21, 2023

Expires: March 20, 2024

10 Capsule Summary Slidesets

Activities

MOMENTUM Update
MOMENTUM: Updated Analysis of Momelotinib vs Danazol in Symptomatic, Anemic Patients With Myelofibrosis Previously Treated With a JAKi
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2022

Expires: December 11, 2023

Ruxolitinib in CMML
Phase II Expansion Study of Ruxolitinib for the Treatment of Symptomatic CMML
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

STIMULUS-MDS1
STIMULUS-MDS1: Randomized, Placebo-Controlled Phase II Trial of Sabatolimab, a TIM-3 Inhibitor, Plus HMA in Higher-Risk MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2022

Expires: December 12, 2023

Add-on Parsaclisib in MF
Phase II Study of Parsaclisib Add-on Therapy in Patients With Myelofibrosis and Suboptimal Response to Ruxolitinib: Final Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2022

Expires: December 13, 2023

REFINE: Navitoclax + Ruxolitinib for MF
REFINE Cohort 3: Combination Therapy With Navitoclax, a Novel BCL-2 Family Inhibitor, and Ruxolitinib in JAK Inhibitor–Naive Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

Sintra-REV Final Results
Sintra-REV: Final Results of Low-Dose Lenalidomide vs Placebo in Non‒Transfusion Dependent Patients With Low-Risk del(5q) MDS
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

MDS Classification Systems Validation
Retrospective Analysis for Validation of 2022 WHO and ICC Classification Systems for Patients With Myelodysplastic Syndromes
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

Ropeginterferon Alfa-2b in Early MF
Phase II Study of Ropeginterferon Alfa-2b for Patients With Dynamic International Prognostic Scoring System Low/Intermediate-1–Risk, Prefibrotic Primary MF
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

Selinexor + Ruxolitinib for MF
Phase I Trial of Selinexor With Ruxolitinib in Previously Untreated Myelofibrosis
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

Ruxolitinib in PV and ET
JAK2 V617F Molecular Response to Long-term Ruxolitinib Therapy in Patients With PV and ET
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 19, 2022

Expires: December 18, 2023

Activities

Hematology 2022: MDS and MPNs
Key Studies in Myelodysplastic Syndromes and Myeloproliferative Neoplasms: Independent Conference Coverage of ASH 2022
Conference Coverage
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 16, 2023

Expires: March 15, 2024

8 Capsule Summary Slidesets

Activities

ADVANCE IV: Efgartigimod in ITP
ADVANCE IV: Phase III Trial of IV Efgartigimod in Adults With Primary Immune Thrombocytopenia
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2022

Expires: December 13, 2023

BMT CTN 1703: PTCy + TAC + MMF for GVHD
BMT CTN 1703: Phase III Trial of PTCy + TAC + MMF vs TAC + MTX for Prevention of GVHD Following Reduced-Intensity Conditioning AlloSCT
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

XTEND-1 Pain Outcomes
XTEND-1: Analysis of Pain Scores in Phase III Study of Efanesoctocog Alfa Prophylaxis for Patients With Previously Treated Hemophilia A
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

REACH4: Ruxolitinib in Pediatric aGVHD
REACH4: Phase I/II Study of Ruxolitinib in Pediatric Patients With Untreated or Steroid-Refractory Acute Graft-vs-Host Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 15, 2022

Expires: December 14, 2023

CADENZA: PRO Outcomes
CADENZA: Patient-Reported and Quality-of-Life Outcomes From Phase III Study of Sutimlimab vs Placebo in Patients With Cold Agglutinin Disease
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

ATLAS-PPX HRQoL
ATLAS-PPX: Health-Related Quality of Life With Fitusiran Prophylaxis in Patients With Hemophilia A or B With or Without Inhibitors
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

Vemircopan in Untreated PNH
Phase II Trial of Vemircopan (ALXN2050) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2022

Expires: December 15, 2023

APPLY-PNH: Iptacopan for PNH
APPLY-PNH: Phase III Trial of Iptacopan Monotherapy in Patients With Paroxysmal Nocturnal Hemoglobinuria and Residual Anemia With Anti-C5 Therapy
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2022

Expires: December 16, 2023

Activities

Hematology 2022: Nonmalignant diseases
Key Studies in Nonmalignant Hematology: Independent Conference Coverage of ASH 2022
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: March 23, 2023

Expires: March 22, 2024

Faculty

cover img faculity

Catherine M. Broome, MD

Professor of Medicine
Division of Hematology/Oncology
MedStar Georgetown University Hospital
Washington, DC

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

cover img faculity

Corey Cutler, MD, MPH, FRCPC

Associate Professor of Medicine
Harvard Medical School
Medical Director, Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, Massachusetts

cover img faculity

David Dingli, MD, PhD

Professor of Medicine
Division of Hematology
Mayo Clinic College of Science and Medicine
Rochester, Minnesota

cover img faculity

Amir Fathi, MD

Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Division of Hematology/Oncology
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

cover img faculity

Amir T. Fathi, MD

Director, Leukemia Program
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Chair, Myeloma Amyloidosis Dysproteinemia Group
Consultant, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

cover img faculity

Peter Martin, MD

Chief, Lymphoma Program
Professor of Medicine
Weill Cornell Medicine
Meyer Cancer Center
New York, New York

cover img faculity

Marshall Mazepa, MD

Assistant Professor of Medicine
Division of Hematology, Oncology and Transplantation
University of Minnesota
Minneapolis, Minnesota

cover img faculity

Srdan Verstovsek, MD, PhD

Professor
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

cover img faculity

Eunice S. Wang, MD

Chief, Leukemia/Benign Hematology Service
Professor of Oncology
Roswell Park Comprehensive Cancer Center
Buffalo, New York

cover img faculity

Allison Wheeler, MD, MSCI

Associate Professor
Department of Pathology, Microbiology, and Immunology
Department of Pediatrics
Vanderbilt University Medical Center
Nashville, Tennessee

cover img faculity

Amer Zeidan, MBBS, MPH

Associate Professor of Medicine (Hematology)
Chief, Division of Hematologic Malignancies
Yale Comprehensive Cancer Center and Smilow Cancer Hospital
New Haven, Connecticut

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.